Literature DB >> 15623633

MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course.

Wei Xin1, Ki J Yun, Francesca Ricci, Marianna Zahurak, Wanglong Qiu, Gloria H Su, Charles J Yeo, Ralph H Hruban, Scott E Kern, Christine A Iacobuzio-Donahue.   

Abstract

MKK4 (MAP2K4/SEK1) is a member of the mitogen-activated protein kinase family, originally identified as a kinase involved in the stress-activated protein kinase pathway by directly phosphorylating c-Jun NH2-terminal kinase. MKK4 genetic inactivation has been observed in a subset of pancreatic carcinomas, implicating deregulation of the stress-activated protein kinase pathway in pancreatic carcinogenesis. We evaluated Mkk4 protein expression patterns by immunohistochemical labeling in a series of 60 resected primary infiltrating pancreatic adenocarcinomas (24 cases with known MKK4 genetic status), and 14 different tissue arrays representing the primary carcinoma and all of the gross metastases from 26 patients that died of metastatic pancreatic cancer. Among the surgically resected carcinomas, focal or diffuse-positive immunolabeling for Mkk4 protein was found in 52 of 60 cases (86.7%). Among the eight carcinomas with negative Mkk4 immunolabeling, three harbored a homozygous deletion or intragenic mutation of the MKK4 gene, in contrast to none of the 52 cases with positive Mkk4 immunolabeling (P < 0.01). Loss of Mkk4 immunolabeling showed a trend toward shorter survival, with Mkk4-positive carcinomas having half the risk of death than Mkk4-negative carcinomas (P = 0.09). Mkk4 immunolabeling patterns were also evaluated among unresectable primary and metastatic cancer tissues from autopsy specimens, indicating intact Mkk4 immunolabeling in 88.8% of the unresectable primary carcinomas as compared with 63.3% of distant metastases (P < 0.001). Our data indicate that the loss of Mkk4 protein expression in pancreatic carcinomas may be more frequent than suggested by the rates of genetic inactivation alone and that MKK4 loss may contribute to disease progression. The correlation of MKK4 genetic status with immunolabeling patterns validate this approach for the evaluation of MKK4 status in routine histologic sections and may provide useful information regarding patient prognosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15623633     DOI: 10.1158/1078-0432.CCR-04-0885

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

Review 1.  The c-jun kinase/stress-activated pathway: regulation, function and role in human disease.

Authors:  Gary L Johnson; Kazuhiro Nakamura
Journal:  Biochim Biophys Acta       Date:  2007-01-04

2.  Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.

Authors:  Monique A Spillman; Judith Lacy; Susan K Murphy; Regina S Whitaker; Lisa Grace; Vanessa Teaberry; Jeffrey R Marks; Andrew Berchuck
Journal:  Gynecol Oncol       Date:  2007-02-05       Impact factor: 5.482

3.  Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy.

Authors:  Emmet J Jordan; Olca Basturk; Jinru Shia; David S Klimstra; William Alago; Michael I D'Angelica; Ghassan K Abou-Alfa; Eileen M O'Reilly; Maeve A Lowery
Journal:  J Gastrointest Oncol       Date:  2017-10

4.  MKK4 acts as a potential tumor suppressor in ovarian cancer.

Authors:  Shamima Yeasmin; Kentaro Nakayama; Mohammed Tanjimur Rahman; Munmun Rahman; Masako Ishikawa; Atsuko Katagiri; Kouji Iida; Naomi Nakayama; Kohji Miyazaki
Journal:  Tumour Biol       Date:  2011-04-14

5.  MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.

Authors:  Xiaozhen Wu; Zuode Gong; Lanying Sun; Long Ma; Qibao Wang
Journal:  Cell Prolif       Date:  2017-03-20       Impact factor: 6.831

6.  [Coexpression of MAP2K4 and vimentin proteins in human endometrial carcinoma and its clinicopathological significance].

Authors:  Chun-Hua Liu; Qing-Ping Jiang; Dan Lin; Wei Chen; Yan-Yi Xiao; Li Lin; Yuan-Run Deng; Hui-Ping Jiang; Sui-Qun Guo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-02-20

7.  A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma.

Authors:  Vincent W Keng; Augusto Villanueva; Derek Y Chiang; Adam J Dupuy; Barbara J Ryan; Ilze Matise; Kevin A T Silverstein; Aaron Sarver; Timothy K Starr; Keiko Akagi; Lino Tessarollo; Lara S Collier; Scott Powers; Scott W Lowe; Nancy A Jenkins; Neal G Copeland; Josep M Llovet; David A Largaespada
Journal:  Nat Biotechnol       Date:  2009-02-22       Impact factor: 54.908

Review 8.  Pancreatic carcinogenesis.

Authors:  Jan-Bart M Koorstra; Steven R Hustinx; G Johan A Offerhaus; Anirban Maitra
Journal:  Pancreatology       Date:  2008-04-01       Impact factor: 3.996

9.  Gene expression profiles associated with advanced pancreatic cancer.

Authors:  Domenico Campagna; Leslie Cope; Sindhu S Lakkur; Clark Henderson; Daniel Laheru; Christine A Iacobuzio-Donahue
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 10.  Pancreatic cancer.

Authors:  Anirban Maitra; Ralph H Hruban
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.